Top

Published in:

01-06-2020 | Leishmania | Review

Leishmaniasis immunopathology—impact on design and use of vaccines, diagnostics and drugs

Authors: Paul M. Kaye, Israel Cruz, Albert Picado, Katrien Van Bocxlaer, Simon L. Croft

Published in: Seminars in Immunopathology | Issue 3/2020

Abstract

Leishmaniasis is a disease complex caused by 20 species of protozoan parasites belonging to the genus Leishmania. In humans, it has two main clinical forms, visceral leishmaniasis (VL) and cutaneous or tegumentary leishmaniasis (CL), as well as several other cutaneous manifestations in a minority of cases. In the mammalian host Leishmania parasites infect different populations of macrophages where they multiply and survive in the phagolysosomal compartment. The progression of both VL and CL depends on the maintenance of a parasite-specific immunosuppressive state based around this host macrophage infection. The complexity and variation of immune responses and immunopathology in humans and the different host interactions of the different Leishmania species has an impact upon the effectiveness of vaccines, diagnostics and drugs.

Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7(5):e35671CrossRef

Burza S, Croft SL, Boelaert M (2018) Leishmaniasis. Lancet 392(10151):951–970. https://doi.org/10.1016/s0140-6736(18)31204-2 CrossRefPubMed

Mukhopadhyay D, Dalton JE, Kaye PM, Chatterjee M (2014) Post kala-azar dermal leishmaniasis: an unresolved mystery. Trends Parasitol 30(2):65–74. https://doi.org/10.1016/j.pt.2013.12.004 CrossRefPubMedPubMedCentral

Sacks DL (1989) Metacyclogenesis in Leishmania promastigotes. Exp Parasitol 69(1):100–103CrossRef

Dostalova A, Volf P (2012) Leishmania development in sand flies: parasite-vector interactions overview. Parasit Vectors 5:276. https://doi.org/10.1186/1756-3305-5-276 CrossRefPubMedPubMedCentral

Serafim TD, Coutinho-Abreu IV, Oliveira F, Meneses C, Kamhawi S, Valenzuela JG (2018) Sequential blood meals promote Leishmania replication and reverse metacyclogenesis augmenting vector infectivity. Nat Microbiol 3(5):548–555. https://doi.org/10.1038/s41564-018-0125-7 CrossRefPubMedPubMedCentral

Kloehn J, Saunders EC, O’Callaghan S, Dagley MJ, McConville MJ (2015) Characterization of metabolically quiescent Leishmania parasites in murine lesions using heavy water labeling. PLoS Pathog 11(2):e1004683. https://doi.org/10.1371/journal.ppat.1004683 CrossRefPubMedPubMedCentral

Mandell MA, Beverley SM (2017) Continual renewal and replication of persistent Leishmania major parasites in concomitantly immune hosts. Proc Natl Acad Sci U S A 114(5):E801–e810. https://doi.org/10.1073/pnas.1619265114 CrossRefPubMedPubMedCentral

Burchmore RJS, Barrett MP (2001) Life in vacuoles – nutrient acquisition by Leishmania amastigotes. Int J Parasitol 31(12):1311–1320. https://doi.org/10.1016/S0020-7519(01)00259-4 CrossRefPubMed

10.

Rogers ME, Chance ML, Bates PA (2002) The role of promastigote secretory gel in the origin and transmission of the infective stage of Leishmania mexicana by the sandfly Lutzomyia longipalpis. Parasitology 124:495–507CrossRef

11.

Giraud E, Svobodova M, Muller I, Volf P, Rogers ME (2019) Promastigote secretory gel from natural and unnatural sand fly vectors exacerbate Leishmania major and Leishmania tropica cutaneous leishmaniasis in mice. Parasitology:1–7. https://doi.org/10.1017/s0031182019001069

12.

Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Conceicao-Silva F, Modlin RL (1993) Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest 91(4):1390–1395. https://doi.org/10.1172/jci116341 CrossRefPubMedPubMedCentral

13.

Nylen S, Sacks D (2007) Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol 28(9):378–384. https://doi.org/10.1016/j.it.2007.07.004 CrossRefPubMed

14.

Caldas A, Favali C, Aquino D, Vinhas V, van Weyenbergh J, Brodskyn C, Costa J, Barral-Netto M, Barral A (2005) Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis. BMC Infect Dis 5:113–113. https://doi.org/10.1186/1471-2334-5-113 CrossRefPubMedPubMedCentral

15.

Kaye P, Scott P (2011) Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol 9(8):604–615CrossRef

16.

Scott P, Novais FO (2016) Cutaneous leishmaniasis: immune responses in protection and pathogenesis. Nat Rev Immunol 16(9):581–592. https://doi.org/10.1038/nri.2016.72 CrossRefPubMed

17.

Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, Arenas R (2017) Leishmaniasis: a review. F1000Research 6:750. https://doi.org/10.12688/f1000research.11120.1 CrossRefPubMedPubMedCentral

18.

Atayde VD, Hassani K, da Silva Lira Filho A, Borges AR, Adhikari A, Martel C, Olivier M (2016) Leishmania exosomes and other virulence factors: impact on innate immune response and macrophage functions. Cell Immunol 309:7–18. https://doi.org/10.1016/j.cellimm.2016.07.013 CrossRefPubMed

19.

Biedermann T, Zimmermann S, Himmelrich H, Gumy A, Egeter O, Sakrauski AK, Seegmuller I, Voigt H, Launois P, Levine AD, Wagner H, Heeg K, Louis JA, Rocken M (2001) IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat Immunol 2(11):1054–1060. https://doi.org/10.1038/ni725 CrossRefPubMed

20.

Stager S, Alexander J, Kirby AC, Botto M, Rooijen NV, Smith DF, Brombacher F, Kaye PM (2003) Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nat Med 9(10):1287–1292. https://doi.org/10.1038/nm933 CrossRefPubMed

21.

McFarlane E, Mokgethi T, Kaye PM, Hurdayal R, Brombacher F, Alexander J, Carter KC (2019) IL-4 mediated resistance of BALB/c mice to visceral Leishmaniasis is independent of IL-4Rα signaling via T cells. Front Immunol 10(1957). https://doi.org/10.3389/fimmu.2019.01957

22.

Alexander J, Carter KC, Al-Fasi N, Satoskar A, Brombacher F (2000) Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol 30(10):2935–2943. https://doi.org/10.1002/1521-4141(200010)30:10<2935::aid-immu2935>3.0.co;2-q CrossRefPubMed

23.

Sernee MF, Ralton JE, Nero TL, Sobala LF, Kloehn J, Vieira-Lara MA, Cobbold SA, Stanton L, Pires DEV, Hanssen E, Males A, Ward T, Bastidas LM, van der Peet PL, Parker MW, Ascher DB, Williams SJ, Davies GJ, McConville MJ (2019) A family of dual-activity glycosyltransferase-phosphorylases mediates Mannogen turnover and virulence in Leishmania parasites. Cell Host Microbe 26(3):385–399.e389. https://doi.org/10.1016/j.chom.2019.08.009 CrossRefPubMed

24.

Yona S, Kim KW, Wolf Y, Mildner A, Varol D, Breker M, Strauss-Ayali D, Viukov S, Guilliams M, Misharin A, Hume DA, Perlman H, Malissen B, Zelzer E, Jung S (2013) Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 38(1):79–91. https://doi.org/10.1016/j.immuni.2012.12.001 CrossRefPubMed

25.

Guilliams M, Scott CL (2017) Does niche competition determine the origin of tissue-resident macrophages? Nat Rev Immunol 17(7):451–460. https://doi.org/10.1038/nri.2017.42 CrossRefPubMed

26.

Lee SH, Charmoy M, Romano A, Paun A, Chaves MM, Cope FO, Ralph DA, Sacks DL (2018) Mannose receptor high, M2 dermal macrophages mediate nonhealing Leishmania major infection in a Th1 immune environment. J Exp Med 215(1):357–375. https://doi.org/10.1084/jem.20171389 CrossRefPubMedPubMedCentral

27.

Beattie L, Sawtell A, Mann J, Frame TCM, Teal B, de Labastida RF, Brown N, Walwyn-Brown K, Moore JWJ, MacDonald S, Lim EK, Dalton JE, Engwerda CR, MacDonald KP, Kaye PM (2016) Bone marrow-derived and resident liver macrophages display unique transcriptomic signatures but similar biological functions. J Hepatol 65(4):758–768. https://doi.org/10.1016/j.jhep.2016.05.037 CrossRefPubMedPubMedCentral

28.

Heyde S, Philipsen L, Formaglio P, Fu Y, Baars I, Hobbel G, Kleinholz CL, Seiss EA, Stettin J, Gintschel P, Dudeck A, Bousso P, Schraven B, Muller AJ (2018) CD11c-expressing Ly6C+CCR2+ monocytes constitute a reservoir for efficient Leishmania proliferation and cell-to-cell transmission. PLoS Pathog 14(10):e1007374. https://doi.org/10.1371/journal.ppat.1007374 CrossRefPubMedPubMedCentral

29.

Romano A, Carneiro MBH, Doria NA, Roma EH, Ribeiro-Gomes FL, Inbar E, Lee SH, Mendez J, Paun A, Sacks DL, Peters NC (2017) Divergent roles for Ly6C+CCR2+CX3CR1+ inflammatory monocytes during primary or secondary infection of the skin with the intra-phagosomal pathogen Leishmania major. PLoS Pathog 13(6):e1006479. https://doi.org/10.1371/journal.ppat.1006479 CrossRefPubMedPubMedCentral

30.

Terrazas C, Varikuti S, Oghumu S, Steinkamp HM, Ardic N, Kimble J, Nakhasi H, Satoskar AR (2017) Ly6C(hi) inflammatory monocytes promote susceptibility to Leishmania donovani infection. Sci Rep 7(1):14693. https://doi.org/10.1038/s41598-017-14935-3 CrossRefPubMedPubMedCentral

31.

Tiburcio R, Nunes S, Nunes I, Rosa Ampuero M, Silva IB, Lima R, Machado Tavares N, Brodskyn C (2019) Molecular aspects of dendritic cell activation in Leishmaniasis: an immunobiological view. Front Immunol 10:227. https://doi.org/10.3389/fimmu.2019.00227 CrossRefPubMedPubMedCentral

32.

Hurrell BP, Regli IB, Tacchini-Cottier F (2016) Different Leishmania species drive distinct neutrophil functions. Trends Parasitol 32(5):392–401. https://doi.org/10.1016/j.pt.2016.02.003 CrossRefPubMed

33.

Pinto AI, Brown N, Preham O, Doehl JSP, Ashwin H, Kaye PM (2017) TNF signalling drives expansion of bone marrow CD4+ T cells responsible for HSC exhaustion in experimental visceral leishmaniasis. PLoS Pathog 13(7):e1006465. https://doi.org/10.1371/journal.ppat.1006465 CrossRefPubMedPubMedCentral

34.

Abidin BM, Hammami A, Stager S, Heinonen KM (2017) Infection-adapted emergency hematopoiesis promotes visceral leishmaniasis. PLoS Pathog 13(8):e1006422. https://doi.org/10.1371/journal.ppat.1006422 CrossRefPubMedPubMedCentral

35.

Kaye PM, Beattie L (2016) Lessons from other diseases: granulomatous inflammation in leishmaniasis. Semin Immunopathol 38(2):249–260. https://doi.org/10.1007/s00281-015-0548-7 CrossRefPubMed

36.

Angarano G, Maggi P, Rollo MA, Larocca AM, Quarto M, Scalone A, Gradoni L (1998) Diffuse necrotic hepatic lesions due to visceral leishmaniasis in AIDS. J infect 36(2):167–169. https://doi.org/10.1016/s0163-4453(98)80007-8 CrossRefPubMed

37.

Yazici P, Yeniay L, Aydin U, Tasbakan M, Ozutemiz O, Yilmaz R (2008) Visceral leishmaniasis as a rare cause of granulomatosis hepatitis: a case report. Turkiye parazitolojii dergisi 32(1):12–15PubMed

38.

Boussoffara T, Boubaker MS, Ben Ahmed M, Mokni M, Guizani I, Ben Salah A, Louzir H (2019) Histological and immunological differences between zoonotic cutaneous leishmaniasis due to Leishmania major and sporadic cutaneous leishmaniasis due to Leishmania infantum. Parasite (Paris, France) 26:9. https://doi.org/10.1051/parasite/2019007 CrossRef

39.

Sandoval Pacheco CM, Araujo Flores GV, Favero Ferreira A, Sosa Ochoa W, Ribeiro da Matta VL, Zuniga Valeriano C, Pereira Corbett CE, Dalastra Laurenti M (2018) Histopathological features of skin lesions in patients affected by non-ulcerated or atypical cutaneous leishmaniasis in Honduras, Central America. Int J Exp Pathol 99(5):249–257. https://doi.org/10.1111/iep.12295 CrossRefPubMedPubMedCentral

40.

Thilakarathne IK, Ratnayake P, Vithanage A, Sugathadasa DP (2019) Role of histopathology in the diagnosis of cutaneous Leishmaniasis: a case-control study in Sri Lanka. Am J Dermatopathol 41(8):566–570. https://doi.org/10.1097/dad.0000000000001367 CrossRefPubMed

41.

Grimaldi G Jr, Teva A, Porrozzi R, Pinto MA, Marchevsky RS, Rocha MG, Dutra MS, Bruna-Romero O, Fernandes AP, Gazzinelli RT (2014) Clinical and parasitological protection in a Leishmania infantum-macaque model vaccinated with adenovirus and the recombinant A2 antigen. PLoS Negl Trop Dis 8(6):e2853. https://doi.org/10.1371/journal.pntd.0002853 CrossRefPubMedPubMedCentral

42.

Khamesipour A, Dowlati Y, Asilian A, Hashemi-Fesharki R, Javadi A, Noazin S, Modabber F (2005) Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 23(28):3642–3648. https://doi.org/10.1016/j.vaccine.2005.02.015 CrossRefPubMed

43.

Mebius RE, Kraal G (2005) Structure and function of the spleen. Nat Rev Immunol 5(8):606–616. https://doi.org/10.1038/nri1669 CrossRefPubMed

44.

Kaye PM (2018) Stromal cell responses in infection. Adv Exp Med Biol 1060:23–36. https://doi.org/10.1007/978-3-319-78127-3_2 CrossRefPubMed

45.

Stanley AC, Engwerda CR (2007) Balancing immunity and pathology in visceral leishmaniasis. Immunol Cell Biol 85(2):138–147. https://doi.org/10.1038/sj.icb7100011 CrossRefPubMed

46.

Hermida MD, de Melo CVB, Lima IDS, Oliveira GGS, Dos-Santos WLC (2018) Histological disorganization of spleen compartments and severe visceral Leishmaniasis. Front Cell Infect Microbiol 8:394. https://doi.org/10.3389/fcimb.2018.00394 CrossRefPubMedPubMedCentral

47.

Gardinassi LG, Garcia GR, Costa CH, Costa Silva V, de Miranda Santos IK (2016) Blood transcriptional profiling reveals immunological signatures of distinct states of infection of humans with Leishmania infantum. PLoS Negl Trop Dis 10(11):e0005123. https://doi.org/10.1371/journal.pntd.0005123 CrossRefPubMedPubMedCentral

48.

Fakiola M, Singh OP, Syn G, Singh T, Singh B, Chakravarty J, Sundar S, Blackwell JM (2019) Transcriptional blood signatures for active and amphotericin B treated visceral leishmaniasis in India. PLoS Negl Trop Dis 13(8):e0007673. https://doi.org/10.1371/journal.pntd.0007673 CrossRefPubMedPubMedCentral

49.

Ashwin H, Seifert K, Forrester S, Brown N, MacDonald S, James S, Lagos D, Timmis J, Mottram JC, Croft SL, Kaye PM (2018) Tissue and host species-specific transcriptional changes in models of experimental visceral leishmaniasis. Wellcome Open Research 3:135. https://doi.org/10.12688/wellcomeopenres.14867.2 CrossRefPubMed

50.

Kong F, Saldarriaga OA, Spratt H, Osorio EY, Travi BL, Luxon BA, Melby PC (2017) Transcriptional profiling in experimental visceral Leishmaniasis reveals a broad splenic inflammatory environment that conditions macrophages toward a disease-promoting phenotype. PLoS Pathog 13(1):e1006165. https://doi.org/10.1371/journal.ppat.1006165 CrossRefPubMedPubMedCentral

51.

Loria-Cervera EN, Andrade-Narvaez FJ (2014) Animal models for the study of leishmaniasis immunology. Rev Inst Med Trop Sao Paulo 56(1):1–11. https://doi.org/10.1590/s0036-46652014000100001 CrossRefPubMedPubMedCentral

52.

Carvalho LP, Passos S, Schriefer A, Carvalho EM (2012) Protective and pathologic immune responses in human tegumentary leishmaniasis. Front Immunol 3:301. https://doi.org/10.3389/fimmu.2012.00301 CrossRefPubMedPubMedCentral

53.

Ives A, Ronet C, Prevel F, Ruzzante G, Fuertes-Marraco S, Schutz F, Zangger H, Revaz-Breton M, Lye LF, Hickerson SM, Beverley SM, Acha-Orbea H, Launois P, Fasel N, Masina S (2011) Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis. Science (New York, NY) 331(6018):775–778. https://doi.org/10.1126/science.1199326 CrossRef

54.

Novais FO, Carvalho AM, Clark ML, Carvalho LP, Beiting DP, Brodsky IE, Carvalho EM, Scott P (2017) CD8+ T cell cytotoxicity mediates pathology in the skin by inflammasome activation and IL-1beta production. PLoS Pathog 13(2):e1006196. https://doi.org/10.1371/journal.ppat.1006196 CrossRefPubMedPubMedCentral

55.

Rossi M, Castiglioni P, Hartley MA, Eren RO, Prevel F, Desponds C, Utzschneider DT, Zehn D, Cusi MG, Kuhlmann FM, Beverley SM, Ronet C, Fasel N (2017) Type I interferons induced by endogenous or exogenous viral infections promote metastasis and relapse of leishmaniasis. Proc Natl Acad Sci U S A 114(19):4987–4992. https://doi.org/10.1073/pnas.1621447114 CrossRefPubMedPubMedCentral

56.

Alvar J, Croft SL, Kaye P, Khamesipour A, Sundar S, Reed SG (2013) Case study for a vaccine against leishmaniasis. Vaccine 31(Suppl 2):B244–B249. https://doi.org/10.1016/j.vaccine.2012.11.080 CrossRefPubMed

57.

Schroeder J, Aebischer T (2011) Vaccines for leishmaniasis: from proteome to vaccine candidates. Hum Vaccin 7(Suppl):10–15. https://doi.org/10.4161/hv.7.0.14556 CrossRefPubMed

58.

Masic A, Hurdayal R, Nieuwenhuizen NE, Brombacher F, Moll H (2012) Dendritic cell-mediated vaccination relies on interleukin-4 receptor signaling to avoid tissue damage after Leishmania major infection of BALB/c mice. PLoS Negl Trop Dis 6(7):e1721. https://doi.org/10.1371/journal.pntd.0001721 CrossRefPubMedPubMedCentral

59.

Majumder S, Bhattacharjee A, Paul Chowdhury B, Bhattacharyya Majumdar S, Majumdar S (2014) Antigen-pulsed CpG-ODN-activated dendritic cells induce host-protective immune response by regulating the T regulatory cell functioning in Leishmania donovani-infected mice: critical role of CXCL10. Front Immunol 5(261). https://doi.org/10.3389/fimmu.2014.00261

60.

Cecilio P, Perez-Cabezas B, Fernandez L, Moreno J, Carrillo E, Requena JM, Fichera E, Reed SG, Coler RN, Kamhawi S, Oliveira F, Valenzuela JG, Gradoni L, Glueck R, Gupta G, Cordeiro-da-Silva A (2017) Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis. PLoS Negl Trop Dis 11(11):e0005951. https://doi.org/10.1371/journal.pntd.0005951 CrossRefPubMedPubMedCentral

61.

Das S, Freier A, Boussoffara T, Das S, Oswald D, Losch FO, Selka M, Sacerdoti-Sierra N, Schonian G, Wiesmuller KH, Seifert K, Schroff M, Juhls C, Jaffe CL, Roy S, Das P, Louzir H, Croft SL, Modabber F, Walden P (2014) Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis. Sci Transl Med 6(234):234ra256. https://doi.org/10.1126/scitranslmed.3008222 CrossRef

62.

Osman M, Mistry A, Keding A, Gabe R, Cook E, Forrester S, Wiggins R, Di Marco S, Colloca S, Siani L, Cortese R, Smith DF, Aebischer T, Kaye PM, Lacey CJ (2017) A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH. PLoS Negl Trop Dis 11(5):e0005527. https://doi.org/10.1371/journal.pntd.0005527 CrossRefPubMedPubMedCentral

63.

Gannavaram S, Torcivia J, Gasparyan L, Kaul A, Ismail N, Simonyan V, Nakhasi HL (2017) Whole genome sequencing of live attenuated Leishmania donovani parasites reveals novel biomarkers of attenuation and enables product characterization. Sci Rep 7(1):4718. https://doi.org/10.1038/s41598-017-05088-4 CrossRefPubMedPubMedCentral

64.

Maroof A, Brown N, Smith B, Hodgkinson MR, Maxwell A, Losch FO, Fritz U, Walden P, Lacey CN, Smith DF, Aebischer T, Kaye PM (2012) Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis. J Infect Dis 205(5):853–863. https://doi.org/10.1093/infdis/jir842 CrossRefPubMedPubMedCentral

65.

Toepp A, Larson M, Wilson G, Grinnage-Pulley T, Bennett C, Leal-Lima A, Anderson B, Parrish M, Anderson M, Fowler H, Hinman J, Kontowicz E, Jefferies J, Beeman M, Buch J, Saucier J, Tyrrell P, Gharpure R, Cotter C, Petersen C (2018) Randomized, controlled, double-blinded field trial to assess Leishmania vaccine effectiveness as immunotherapy for canine leishmaniosis. Vaccine 36(43):6433–6441. https://doi.org/10.1016/j.vaccine.2018.08.087 CrossRefPubMed

66.

WHO (2016) Leishmaniasis in high-burden countries: An epidemiological update based on data reported in 2014 WHO Weekly epidemiological record 22 (91):285–296

67.

Organization WECotCotLWH (2010) Control of the leishmaniases: report of a meeting of the WHO expert committee on the control of Leishmaniases vol 949. World Health Organization, Geneva

68.

Ghose AC, Haldar JP, Pal SC, Mishra BP, Mishra KK (1980) Serological investigations on Indian kala-azar. Clin Exp Immunol 40(2):318–326PubMedPubMedCentral

69.

Boelaert M, Verdonck K, Menten J, Sunyoto T, van Griensven J, Chappuis F, Rijal S (2014) Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease. The Cochrane database of systematic reviews (6):Cd009135. https://doi.org/10.1002/14651858.CD009135.pub2

70.

Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M (2007) Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5(11):873–882CrossRef

71.

Bhattacharyya T, Boelaert M, Miles MA (2013) Comparison of visceral leishmaniasis diagnostic antigens in African and Asian Leishmania donovani reveals extensive diversity and region-specific polymorphisms. PLoS Negl Trop Dis 7(2):e2057. https://doi.org/10.1371/journal.pntd.0002057 CrossRefPubMedPubMedCentral

72.

Bhattacharyya T, Bowes DE, El-Safi S, Sundar S, Falconar AK, Singh OP, Kumar R, Ahmed O, Boelaert M, Miles MA (2014) Significantly lower anti-Leishmania IgG responses in Sudanese versus Indian visceral leishmaniasis. PLoS Negl Trop Dis 8(2):e2675. https://doi.org/10.1371/journal.pntd.0002675 CrossRefPubMedPubMedCentral

73.

Pattabhi S, Whittle J, Mohamath R, El-Safi S, Moulton GG, Guderian JA, Colombara D, Abdoon AO, Mukhtar MM, Mondal D, Esfandiari J, Kumar S, Chun P, Reed SG, Bhatia A (2010) Design, development and evaluation of rK28-based point-of-care tests for improving rapid diagnosis of visceral leishmaniasis. PLoS Negl Trop Dis 4(9). https://doi.org/10.1371/journal.pntd.0000822

74.

Bezuneh A, Mukhtar M, Abdoun A, Teferi T, Takele Y, Diro E, Jemaneh A, Shiferaw W, Wondimu H, Bhatia A, Howard RF, Ghalib H, Ireton GC, Hailu A, Reed SG (2014) Comparison of point-of-care tests for the rapid diagnosis of visceral leishmaniasis in East African patients. Am J Trop Med Hyg 91(6):1109–1115. https://doi.org/10.4269/ajtmh.13-0759 CrossRefPubMedPubMedCentral

75.

Mukhtar M, Abdoun A, Ahmed AE, Ghalib H, Reed SG, Boelaert M, Menten J, Khair MM, Howard RF (2015) Diagnostic accuracy of rK28-based immunochromatographic rapid diagnostic tests for visceral leishmaniasis: a prospective clinical cohort study in Sudan. Trans R Soc Trop Med Hyg 109(9):594–600. https://doi.org/10.1093/trstmh/trv060 CrossRefPubMed

76.

Mukhtar M, Ali SS, Boshara SA, Albertini A, Monnerat S, Bessell P, Mori Y, Kubota Y, Ndung'u JM, Cruz I (2018) Sensitive and less invasive confirmatory diagnosis of visceral leishmaniasis in Sudan using loop-mediated isothermal amplification (LAMP). PLoS Negl Trop Dis 12(2):e0006264. https://doi.org/10.1371/journal.pntd.0006264 CrossRefPubMedPubMedCentral

77.

Subramaniam KS, Austin V, Schocker NS, Montoya AL, Anderson MS, Ashmus RA, Mesri M, Al-Salem W, Almeida IC, Michael K, Acosta-Serrano A (2018) Anti-alpha-Gal antibodies detected by novel neoglycoproteins as a diagnostic tool for Old World cutaneous leishmaniasis caused by Leishmania major. Parasitology 145(13):1758–1764. https://doi.org/10.1017/s0031182018000860 CrossRefPubMed

78.

Monge-Maillo B, Norman FF, Cruz I, Alvar J, Lopez-Velez R (2014) Visceral leishmaniasis and HIV coinfection in the Mediterranean region. PLoS Negl Trop Dis 8(8):e3021. https://doi.org/10.1371/journal.pntd.0003021 CrossRefPubMedPubMedCentral

79.

Diro E, Lynen L, Ritmeijer K, Boelaert M, Hailu A, van Griensven J (2014) Visceral Leishmaniasis and HIV coinfection in East Africa. PLoS Negl Trop Dis 8(6):e2869. https://doi.org/10.1371/journal.pntd.0002869 CrossRefPubMedPubMedCentral

80.

Gidwani K, Picado A, Ostyn B, Singh SP, Kumar R, Khanal B, Lejon V, Chappuis F, Boelaert M, Sundar S (2011) Persistence of Leishmania donovani antibodies in past visceral leishmaniasis cases in India. Clin Vaccine Immunol 18(2):346–348. https://doi.org/10.1128/cvi.00473-10 CrossRefPubMed

81.

Bhattacharyya T, Ayandeh A, Falconar AK, Sundar S, El-Safi S, Gripenberg MA, Bowes DE, Thunissen C, Singh OP, Kumar R, Ahmed O, Eisa O, Saad A, Silva Pereira S, Boelaert M, Mertens P, Miles MA (2014) IgG1 as a potential biomarker of post-chemotherapeutic relapse in visceral leishmaniasis, and adaptation to a rapid diagnostic test. PLoS Negl Trop Dis 8(10):e3273. https://doi.org/10.1371/journal.pntd.0003273 CrossRefPubMedPubMedCentral

82.

Marlais T, Bhattacharyya T, Singh OP, Mertens P, Gilleman Q, Thunissen C, Hinckel BCB, Pearson C, Gardner BL, Airs S, de la Roche M, Hayes K, Hafezi H, Falconar AK, Eisa O, Saad A, Khanal B, Bhattarai NR, Rijal S, Boelaert M, El-Safi S, Sundar S, Miles MA (2018) Visceral Leishmaniasis IgG1 rapid monitoring of cure vs. relapse, and potential for diagnosis of post kala-azar dermal Leishmaniasis. Front Cell Infect Microbiol 8:427. https://doi.org/10.3389/fcimb.2018.00427 CrossRefPubMedPubMedCentral

83.

Mollett G, Bremer Hinckel BC, Bhattacharyya T, Marlais T, Singh OP, Mertens P, Falconar AK, El-Safi S, Sundar S, Miles MA (2019) Detection of immunoglobulin G1 against rK39 improves monitoring of treatment outcomes in visceral Leishmaniasis. Clin Infect Dis 69(7):1130–1135. https://doi.org/10.1093/cid/ciy1062 CrossRefPubMed

84.

Kohanteb J, Ardehali SM, Rezai HR (1987) Detection of Leishmania donovani soluble antigen and antibody in the urine of visceral leishmaniasis patients. Trans R Soc Trop Med Hyg 81(4):578–580. https://doi.org/10.1016/0035-9203(87)90414-7 CrossRefPubMed

85.

De Colmenares M, Portus M, Riera C, Gallego M, Aisa MJ, Torras S, Munoz C (1995) Short report: detection of 72-75-kD and 123-kD fractions of Leishmania antigen in urine of patients with visceral leishmaniasis. Am J Trop Med Hyg 52(5):427–428. https://doi.org/10.4269/ajtmh.1995.52.427 CrossRefPubMed

86.

Azazy AA, Chance ML, Devaney E (1997) A time-course study of circulating antigen and parasite-specific antibody in cotton rats infected with Leishmania donovani. Ann Trop Med Parasitol 91(2):153–162. https://doi.org/10.1080/00034983.1997.11813125 CrossRefPubMed

87.

Vallur AC, Tutterrow YL, Mohamath R, Pattabhi S, Hailu A, Abdoun AO, Ahmed AE, Mukhtar M, Salam MA, Almeida ML, Almeida RP, Mondal D, Albertini A, Ghalib H, Duthie MS, Reed SG (2015) Development and comparative evaluation of two antigen detection tests for visceral Leishmaniasis. BMC Infect Dis 15:384. https://doi.org/10.1186/s12879-015-1125-3 CrossRefPubMedPubMedCentral

88.

Gao CH, Yang YT, Shi F, Wang JY, Steverding D, Wang X (2015) Development of an Immunochromatographic test for diagnosis of visceral Leishmaniasis based on detection of a circulating antigen. PLoS Negl Trop Dis 9(6):e0003902. https://doi.org/10.1371/journal.pntd.0003902 CrossRefPubMedPubMedCentral

89.

Cruz I, Albertini A, Barbeitas M, Arana B, Picado A, Ruiz-Postigo JA, Ndung'u JM (2019) Target product profile for a point-of-care diagnostic test for dermal leishmaniases. Parasite Epidemiol Control 5:e00103. https://doi.org/10.1016/j.parepi.2019.e00103 CrossRefPubMedPubMedCentral

90.

Ben Salah A, Zaatour A, Gharbi A, Bettaieb J, Ghawar W, Khedher a Clinical evaluation of CL detect TM rapid test for cutaneous leishmaniasis: performance characteristics when compared to smear microscopy at multiple test sites. In: ASTMH, New Orleans, 2014

91.

Bennis I, Verdonck K, El Khalfaoui N, Riyad M, Fellah H, Dujardin JC, Sahibi H, Bouhout S, Van der Auwera G, Boelaert M (2018) Accuracy of a rapid diagnostic test based on antigen detection for the diagnosis of cutaneous Leishmaniasis in patients with suggestive skin lesions in Morocco. Am J Trop Med Hyg 99(3):716–722. https://doi.org/10.4269/ajtmh.18-0066 CrossRefPubMedPubMedCentral

92.

Vink MMT, Nahzat SM, Rahimi H, Buhler C, Ahmadi BA, Nader M, Zazai FR, Yousufzai AS, van Loenen M, Schallig H, Picado A, Cruz I (2018) Evaluation of point-of-care tests for cutaneous leishmaniasis diagnosis in Kabul, Afghanistan. EBioMedicine 37:453–460. https://doi.org/10.1016/j.ebiom.2018.10.063 CrossRefPubMedPubMedCentral

93.

de Ruiter CM, van der Veer C, Leeflang MM, Deborggraeve S, Lucas C, Adams ER (2014) Molecular tools for diagnosis of visceral leishmaniasis: systematic review and meta-analysis of diagnostic test accuracy. J Clin Microbiol 52(9):3147–3155. https://doi.org/10.1128/jcm.00372-14 CrossRefPubMedPubMedCentral

94.

Weigle KA, Labrada LA, Lozano C, Santrich C, Barker DC (2002) PCR-based diagnosis of acute and chronic cutaneous leishmaniasis caused by Leishmania (Viannia). J Clin Microbiol 40(2):601–606. https://doi.org/10.1128/jcm.40.2.601-606.2002 CrossRefPubMedPubMedCentral

95.

Eroglu F, Uzun S, Koltas IS (2014) Comparison of clinical samples and methods in chronic cutaneous leishmaniasis. Am J Tropical Med Hyg 91(5):895–900. https://doi.org/10.4269/ajtmh.13-0582 CrossRef

96.

Nzelu CO, Kato H, Peters NC (2019) Loop-mediated isothermal amplification (LAMP): an advanced molecular point-of-care technique for the detection of Leishmania infection. PLoS Negl Trop Dis 13(11):e0007698. https://doi.org/10.1371/journal.pntd.0007698 CrossRefPubMedPubMedCentral

97.

Selvapandiyan A, Croft SL, Rijal S, Nakhasi HL, Ganguly NK (2019) Innovations for the elimination and control of visceral leishmaniasis. PLoS Negl Trop Dis 13(9):e0007616. https://doi.org/10.1371/journal.pntd.0007616 CrossRefPubMedPubMedCentral

98.

WHO (2017) Integrating neglected tropical diseases into global health and development: fourth WHO report on neglected tropical diseases. World Health Organisation,

99.

Rijal S, Sundar S, Mondal D, Das P, Alvar J, Boelaert M (2019) Eliminating visceral leishmaniasis in South Asia: the road ahead. BMJ (Clinical research ed) 364:k5224. https://doi.org/10.1136/bmj.k5224 CrossRef

100.

Medley GF, Hollingsworth TD, Olliaro PL, Adams ER (2015) Health-seeking behaviour, diagnostics and transmission dynamics in the control of visceral leishmaniasis in the Indian subcontinent. Nature 528(7580):S102–S108. https://doi.org/10.1038/nature16042 http://www.nature.com/nature/journal/v528/n7580_supp_custom/abs/nature16042.html#supplementary-information CrossRefPubMed

101.

Rijal S, Boelaert M, Regmi S, Karki BM, Jacquet D, Singh R, Chance ML, Chappuis F, Hommel M, Desjeux P, Van der Stuyft P, Le Ray D, Koirala S (2004) Evaluation of a urinary antigen-based latex agglutination test in the diagnosis of kala-azar in eastern Nepal. Trop Med Int Health 9(6):724–729. https://doi.org/10.1111/j.1365-3156.2004.01251.x CrossRefPubMed

102.

Salam MA, Khan MG, Mondal D (2011) Urine antigen detection by latex agglutination test for diagnosis and assessment of initial cure of visceral leishmaniasis. Trans R Soc Trop Med Hyg 105(5):269–272. https://doi.org/10.1016/j.trstmh.2010.12.007 CrossRefPubMed

103.

Attar ZJ, Chance ML, el-Safi S, Carney J, Azazy A, El-Hadi M, Dourado C, Hommel M (2001) Latex agglutination test for the detection of urinary antigens in visceral leishmaniasis. Acta Trop 78(1):11–16. https://doi.org/10.1016/s0001-706x(00)00155-8 CrossRefPubMed

104.

Picado A, Cruz I, Sampath R, Ndung'u JM (2019) An antigen detecting rapid diagnostic test (RDT) to accelerate control and elimination of visceral leishmaniasis. 11th European congress on tropical medicine and international health 113. https://doi.org/10.1093/trstmh/trz0

105.

Molina R, Gradoni L, Alvar J (2003) HIV and the transmission of Leishmania. Ann Trop Med Parasitol 97(Suppl 1):29–45. https://doi.org/10.1179/000349803225002516 CrossRefPubMed

106.

Molina R, Ghosh D, Carrillo E, Monnerat S, Bern C, Mondal D, Alvar J (2017) Infectivity of post-kala-azar dermal Leishmaniasis patients to sand flies: revisiting a proof of concept in the context of the kala-azar elimination program in the Indian subcontinent. Clin Infect Dis 65(1):150–153. https://doi.org/10.1093/cid/cix245 CrossRefPubMedPubMedCentral

107.

Zijlstra EE (2019) Biomarkers in post-kala-azar dermal Leishmaniasis. Front Cell Infect Microbiol 9:228. https://doi.org/10.3389/fcimb.2019.00228 CrossRefPubMedPubMedCentral

108.

Verma S, Avishek K, Sharma V, Negi NS, Ramesh V, Salotra P (2013) Application of loop-mediated isothermal amplification assay for the sensitive and rapid diagnosis of visceral leishmaniasis and post-kala-azar dermal leishmaniasis. Diagn Microbiol Infect Dis 75(4):390–395. https://doi.org/10.1016/j.diagmicrobio.2013.01.011 CrossRefPubMed

109.

Silva-Barrios S, Stager S (2019) Hypergammaglobulinemia sustains the development of regulatory responses during chronic Leishmania donovani infection in mice. Eur J Immunol 49(7):1082–1091. https://doi.org/10.1002/eji.201847917 CrossRefPubMed

110.

da Silva Junior GB, Guardão Barros EJ, De Francesco DE (2014) Kidney involvement in leishmaniasis—a review. Braz J Infect Dis 18(4):434–440. https://doi.org/10.1016/j.bjid.2013.11.013

111.

Cello JP, Day LW (2009) Idiopathic AIDS enteropathy and treatment of gastrointestinal opportunistic pathogens. Gastroenterology 136(6):1952–1965. https://doi.org/10.1053/j.gastro.2008.12.073 CrossRefPubMedPubMedCentral

112.

Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, Carvalho E, Ephros M, Jeronimo S, Magill A (2017) Diagnosis and treatment of Leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Am J Tropical Med Hyg 96(1):24–45. https://doi.org/10.4269/ajtmh.16-84256 CrossRef

113.

González U, Pinart M, Reveiz L, Alvar J (2008) Interventions for Old World cutaneous leishmaniasis. The Cochrane database of systematic reviews 4:111. https://doi.org/10.1002/14651858.CD005067.pub3 CrossRef

114.

González U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA (2009) Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane database systematic reviews 15 (2 (CD004834)):1-171

115.

DNDi (2019) DNDi - Disease projects - Portfolio. Drugs for Neglected Diseases Initiative. https://www.dndi.org/diseases-projects/portfolio/. Accessed 7/11/2019 2019

116.

Khare S, Nagle AS, Biggart A, Lai YH, Liang F, Davis LC, Barnes SW, Mathison CJN, Myburgh E, Gao M-Y, Gillespie JR, Liu X, Tan JL, Stinson M, Rivera IC, Ballard J, Yeh V, Groessl T, Federe G, Koh HXY, Venable JD, Bursulaya B, Shapiro M, Mishra PK, Spraggon G, Brock A, Mottram JC, Buckner FS, Rao SPS, Wen BG, Walker JR, Tuntland T, Molteni V, Glynne RJ, Supek F (2016) Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. Nature 537:229. https://doi.org/10.1038/nature19339 https://www.nature.com/articles/nature19339#supplementary-information CrossRefPubMedPubMedCentral

117.

Thompson AM, O’Connor PD, Marshall AJ, Blaser A, Yardley V, Maes L, Gupta S, Launay D, Braillard S, Chatelain E, Wan B, Franzblau SG, Ma Z, Cooper CB, Denny WA (2018) Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): a new Lead for visceral Leishmaniasis. J Med Chem 61(6):2329–2352. https://doi.org/10.1021/acs.jmedchem.7b01581 CrossRefPubMedPubMedCentral

118.

Van Bocxlaer K, Caridha D, Black C, Vesely B, Leed S, Sciotti RJ, Wijnant GJ, Yardley V, Braillard S, Mowbray CE, Ioset JR, Croft SL (2019) Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis. Int J Parasitol Drugs Drug Resist. https://doi.org/10.1016/j.ijpddr.2019.02.002

119.

Caridha D, Vesely B, van Bocxlaer K, Arana B, Mowbray CE, Rafati S, Uliana S, Reguera R, Kreishman-Deitrick M, Sciotti R, Buffet P, Croft SL (2019) Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis. Int J Parasitol Drugs Drug Resist. https://doi.org/10.1016/j.ijpddr.2019.06.003

120.

Yang JH, Bhargava P, McCloskey D, Mao N, Palsson BO, Collins JJ (2017) Antibiotic-induced changes to the host metabolic environment inhibit drug efficacy and alter immune function. Cell Host Microbe 22(6):757–765.e753. https://doi.org/10.1016/j.chom.2017.10.020 CrossRefPubMedPubMedCentral

121.

Burza S, Mahajan R, Sinha PK, van Griensven J, Pandey K, Lima MA, Sanz MG, Sunyoto T, Kumar S, Mitra G, Kumar R, Verma N, Das P (2014) Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome). PLoS Negl Trop Dis 8(8):e3053. https://doi.org/10.1371/journal.pntd.0003053 CrossRefPubMedPubMedCentral

122.

Adam AAO, Dafalla MMM, Mohammed HA, Elamin MY, Younis BM, Elfaki ME, Musa AM, Elhassan AM, Khalil EAG (2014) Visceral leishmaniasis-hepatitis B/C coinfections: a rising necessity to triage patients for treatment. Ann Saudi Med 34(2):143–146. https://doi.org/10.5144/0256-4947.2014.143 CrossRefPubMedCentral

123.

Hailu W, Weldegebreal T, Hurissa Z, Tafes H, Omollo R, Yifru S, Balasegaram M, Hailu A (2010) Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection. Trans R Soc Trop Med Hyg 104(11):706–712. https://doi.org/10.1016/j.trstmh.2010.07.007 CrossRefPubMed

124.

Mbui J, Olobo J, Omollo R, Solomos A, Kip AE, Kirigi G, Sagaki P, Kimutai R, Were L, Omollo T, Egondi TW, Wasunna M, Alvar J, Dorlo TPC, Alves F (2019) Pharmacokinetics, safety, and efficacy of an Allometric Miltefosine regimen for the treatment of visceral Leishmaniasis in eastern African children: an open-label, phase II clinical trial. Clin Infect Dis 68(9):1530–1538. https://doi.org/10.1093/cid/ciy747 CrossRefPubMed

125.

Murray HW (2000) Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral Miltefosine. Antimicrob Agents Chemother 44(11):3235–3236CrossRef

126.

Murray HW, Delph-Etienne S (2000) Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J Infect Dis 181(2):795–799CrossRef

127.

Escobar P, Yardley V, Croft SL (2001) Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. (0066–4804 (Print))

128.

Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ (2012) Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniaisis. J Antimicrob Chemother 67(11):2576–2597CrossRef

129.

Cohen BE (2016) The role of signaling via aqueous pore formation in resistance responses to amphotericin B. 60 (9):5122-5129. https://doi.org/10.1128/AAC.00878-16

130.

Murray HW, Berman JD, Davies CR, Saravia NG (2005) Advances in leishmaniasis. Lancet 366(9496):1577CrossRef

131.

Chavez-Galan L, Vesin D, Martinvalet D, Garcia I (2016) Low dose BCG infection as a model for macrophage activation maintaining cell viability %J journal of immunology. Research 2016:17. https://doi.org/10.1155/2016/4048235 CrossRef

132.

Convit J, Ulrich M, Zerpa O, Borges R, Aranzazu N, Valera M, Villarroel H, Zapata Z, Tomedes I (2003) Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990-99. Trans R Soc Trop Med Hyg 97(4):469–472. https://doi.org/10.1016/s0035-9203(03)90093-9 CrossRefPubMed

133.

Musa AM, Khalil EAG, Mahgoub FAE, Elgawi SHH, Modabber F, Elkadaru AEMY, Aboud MH, Noazin S, Ghalib HW, El-Hassan AM Group/Sudan TLR (2008) Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans R Soc Trop Med Hyg 102(1):58–63. https://doi.org/10.1016/j.trstmh.2007.08.006

134.

Cohen HA (1979) Induction of delayed-type sensitivity to Leishmania parasite in a case of leishmaniasis cutanea diffusa with BCG and cord-factor (Trehalose-6-6′ dimycolate). Acta Derm Venereol 59(6):547–549. https://doi.org/10.2340/0001555559547549 CrossRefPubMed

135.

Adinolfi LE, Bonventre PF, Vander Pas M, Eppstein DA (1985) Synergistic effect of glucantime and a liposome-encapsulated muramyl dipeptide analog in therapy of experimental visceral leishmaniasis. Infect Immun 48(2):409–416CrossRef

136.

Badaro R, Johnson WD Jr (1993) The role of interferon-gamma in the treatment of visceral and diffuse cutaneous leishmaniasis. J Infect Dis 167(Suppl 1):S13–S17. https://doi.org/10.1093/infdis/167.supplement_1.s13 CrossRefPubMed

137.

Badaro R, Nascimento C, Carvalho JS, Badaro F, Russo D, Ho JL, Reed SG, Johnson WD Jr, Jones TC (1994) Granulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral Leishmaniasis. Eur J Clin Microbiol Infect Dis 13(Suppl 2):S23–S28. https://doi.org/10.1007/bf01973598 CrossRefPubMed

138.

Almeida R, D'Oliveira A Jr, Machado P, Bacellar O, Ko AI, de Jesus AR, Mobashery N, Brito Santos J, Carvalho EM (1999) Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous Leishmaniasis. J Infect Dis 180(5):1735–1737. https://doi.org/10.1086/315082 CrossRefPubMed

139.

Santos JB, de Jesus AR, Machado PR, Magalhaes A, Salgado K, Carvalho EM, Almeida RP (2004) Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous Leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study. J Infect Dis 190(10):1793–1796. https://doi.org/10.1086/424848 CrossRefPubMed

140.

Murray HW (2005) Interleukin 10 receptor blockade--pentavalent antimony treatment in experimental visceral leishmaniasis. Acta Trop 93(3):295–301. https://doi.org/10.1016/j.actatropica.2004.11.008 CrossRefPubMed

141.

Flynn B, Wang V, Sacks DL, Seder RA, Verthelyi D (2005) Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs. Infect Immun 73(8):4948–4954. https://doi.org/10.1128/iai.73.8.4948-4954.2005 CrossRefPubMedPubMedCentral

142.

Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM (2001) Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol (Baltimore, Md : 1950) 166(4):2372–2377. https://doi.org/10.4049/jimmunol.166.4.2372 CrossRef

143.

Buates S, Matlashewski G (1999) Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis 179:1485–1494CrossRef

144.

Arevalo I, Tulliano G, Quispe A, Spaeth G, Matlashewski G, Llanos-Cuentas A, Pollack H (2007) Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 44(12):1549–1554CrossRef

145.

Miranda-Verastegui C, Llanos-Cuentas A, Arevalo I, Ward BJ, Matlashewski G (2005) Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis 40(10):1395–1403CrossRef

146.

Firooz A, Khamesipour A, Ghoorchi MH, Nassiri-Kashani M, Eskandari SE, Khatami A, Hooshmand B, Gorouhi F, Rashighi-Firoozabadi M, Dowlati Y (2006) Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis. Arch Dermatol 142(12):1575–1579CrossRef

147.

El Hajj R, Bou Youness H, Lachaud L, Bastien P, Masquefa C, Bonnet PA, El Hajj H, Khalifeh I (2018) EAPB0503: an Imiquimod analog with potent in vitro activity against cutaneous leishmaniasis caused by Leishmania major and Leishmania tropica. PLoS Negl Trop Dis 12(11):e0006854. https://doi.org/10.1371/journal.pntd.0006854 CrossRefPubMedPubMedCentral

148.

Smith AC, Yardley V, Rhodes J, Croft SL (2000) Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis. Antimicrob Agents Chemother 44(6):1494–1498. https://doi.org/10.1128/aac.44.6.1494-1498.2000 CrossRefPubMedPubMedCentral

149.

Dalton JE, Kaye PM (2010) Immunomodulators: use in combined therapy against leishmaniasis. Expert Rev Anti-Infect Ther 8(7):739–742. https://doi.org/10.1586/eri.10.64 CrossRefPubMed

150.

Machado PR, Lessa H, Lessa M, Guimaraes LH, Bang H, Ho JL, Carvalho EM (2007) Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 44(6):788–793. https://doi.org/10.1086/511643 CrossRefPubMed

151.

Brito G, Dourado M, Polari L, Celestino D, Carvalho LP, Queiroz A, Carvalho EM, Machado PR, Passos S (2014) Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline. Am J Trop Med Hyg 90(4):617–620. https://doi.org/10.4269/ajtmh.12-0729 CrossRefPubMedPubMedCentral

152.

Brito G, Dourado M, Guimaraes LH, Meireles E, Schriefer A, de Carvalho EM, Machado PRL (2017) Oral pentoxifylline associated with pentavalent antimony: a randomized trial for cutaneous Leishmaniasis. Am J Trop Med Hyg 96(5):1155–1159. https://doi.org/10.4269/ajtmh.16-0435 CrossRefPubMedPubMedCentral

153.

Faria DR, Gollob KJ, Barbosa J Jr, Schriefer A, Machado PR, Lessa H, Carvalho LP, Romano-Silva MA, de Jesus AR, Carvalho EM, Dutra WO (2005) Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. Infect Immun 73(12):7853–7859. https://doi.org/10.1128/iai.73.12.7853-7859.2005 CrossRefPubMedPubMedCentral

154.

Sadeghian G, Nilforoushzadeh MA (2006) Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int J Dermatol 45(7):819–821. https://doi.org/10.1111/j.1365-4632.2006.02867.x CrossRefPubMed

155.

Taslimi Y, Zahedifard F, Rafati S (2018) Leishmaniasis and various immunotherapeutic approaches. Parasitology 145(4):497–507. https://doi.org/10.1017/s003118201600216x CrossRefPubMed

156.

Adriaensen W, Dorlo TPC, Vanham G, Kestens L, Kaye PM, van Griensven J (2017) Immunomodulatory therapy of visceral Leishmaniasis in human immunodeficiency virus-coinfected patients. Front Immunol 8:1943. https://doi.org/10.3389/fimmu.2017.01943 CrossRefPubMed

157.

Sakthianandeswaren A, Elso CM, Simpson K, Curtis JM, Kumar B, Speed TP, Handman E, Foote SJ (2005) The wound repair response controls outcome to cutaneous leishmaniasis. Proc Natl Acad Sci U S A 102(43):15551–15556CrossRef

158.

Van Bocxlaer K, Yardley V, Murdan S, Croft SL (2016) Drug permeation and barrier damage in Leishmania-infected mouse skin. J Antimicrob Chemother 71(6):1578–1585. https://doi.org/10.1093/jac/dkw012 CrossRefPubMed

159.

Wijnant GJ, Van Bocxlaer K, Fortes Francisco A, Yardley V, Harris A, Alavijeh M, Murdan S, Croft SL (2018) Local skin inflammation in cutaneous Leishmaniasis as a source of variable pharmacokinetics and therapeutic efficacy of liposomal amphotericin B. Antimicrob Agents Chemother 62(10):e00631–e00618. https://doi.org/10.1128/aac.00631-18 CrossRefPubMedPubMedCentral

160.

Wijnant GJ, Van Bocxlaer K, Yardley V, Harris A, Alavijeh M, Silva-Pedrosa R, Antunes S, Mauricio I, Murdan S, Croft SL (2018) Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome((R)) and AmBisome((R)) in murine cutaneous leishmaniasis. Int J Parasitol Drugs Drug Resist 8 (2):223–228. doi:https://doi.org/10.1016/j.ijpddr.2018.04.001

161.

Coombs GH, Wolf CR, Morrison VM, Craft JA (1990) Changes in hepatic xenobiotic-metabolising enzymes in mouse liver following infection with Leishmania donovani. Mol Biochem Parasitol 41(1):17–24. https://doi.org/10.1016/0166-6851(90)90092-z CrossRefPubMed

162.

Mukhopadhyay R, Madhubala R (1994) Antileishmanial activity and modification of hepatic xenobiotic metabolizing enzymes in golden hamster by 2(3)-tert-butyl-4-hydroxyanisole following infection with Leishmania donovani. Biochem Pharmacol 47(2):253–256. https://doi.org/10.1016/0006-2952(94)90014-0 CrossRefPubMed

163.

Sindermann H, Engel J (2006) Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 100(Suppl 1):S17–S20. https://doi.org/10.1016/j.trstmh.2006.02.010 CrossRefPubMed

164.

Castro MM, Cossio A, Velasco C, Osorio L (2017) Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: a cohort study. PLoS Negl Trop Dis 11(4):e0005515. https://doi.org/10.1371/journal.pntd.0005515 CrossRefPubMedPubMedCentral

165.

Voak AA, Standing JF, Sepulveda N, Harris A, Croft SL, Seifert K (2018) Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani-infected primary macrophages. J Antimicrob Chemother 73(5):1314–1323. https://doi.org/10.1093/jac/dky014 CrossRefPubMedPubMedCentral

166.

Dartois V (2014) The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol 12(3):159–167. https://doi.org/10.1038/nrmicro3200 CrossRefPubMedPubMedCentral

167.

Bryant CE, Monie TP (2012) Mice, men and the relatives: cross-species studies underpin innate immunity. Open Biol 2(4):120015. https://doi.org/10.1098/rsob.120015 CrossRefPubMedPubMedCentral

168.

Zhao M, Lepak AJ, Andes DR (2016) Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. Bioorg Med Chem 24(24):6390–6400. https://doi.org/10.1016/j.bmc.2016.11.008 CrossRefPubMed

Title: Leishmaniasis immunopathology—impact on design and use of vaccines, diagnostics and drugs
Authors: Paul M. Kaye
Israel Cruz
Albert Picado
Katrien Van Bocxlaer
Simon L. Croft
Publication date: 01-06-2020
Publisher: Springer Berlin Heidelberg
Keywords: Leishmania
Visceral Leishmaniasis
Visceral Leishmaniasis
Visceral Leishmaniasis
Leishmania
Cutaneous Leishmaniasis
Cutaneous Leishmaniasis
Published in: Seminars in Immunopathology / Issue 3/2020
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-020-00788-y

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2020

Human unconventional T cells in Plasmodium falciparum infection

Implications of asymptomatic infection for the natural history of selected parasitic tropical diseases

Immunometabolism: new insights and lessons from antigen-directed cellular immune responses

Schistosomiasis—from immunopathology to vaccines

The immunology of other mycobacteria: M. ulcerans, M. leprae

Towards new TB vaccines

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage